Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Inventory Write-down

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Inventory Write-down

AKEBIA THERAPEUTICS, INC. (AKBA) reported Inventory Write-down of $4.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:InventoryWriteDown · last filed 2026-08-05

  • AKEBIA THERAPEUTICS, INC. inventory write-down for the quarter ending 2026-06-30 was $1.73M.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for the quarter ending 2026-03-31 was $3.22M, a 1873.01% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for the quarter ending 2025-12-31 was $1.86M, a 3.05% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for the quarter ending 2025-09-30 was $530.00K, a 60.51% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for fiscal 2025 was $2.50M, a 40.47% decline from fiscal 2024.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for fiscal 2024 was $4.21M, a 166.33% increase from fiscal 2023.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for fiscal 2023 was $1.58M, a 94.77% decline from fiscal 2022.
  • AKEBIA THERAPEUTICS, INC. inventory write-down for fiscal 2022 was $30.20M, a 100.68% increase from fiscal 2021.
Period endInventory Write-down 1 monthInventory Write-down 3 monthInventory Write-down 6 monthInventory Write-down 9 monthInventory Write-down 12 monthInventory Write-down 12 month as first filed
2026-06-30$1.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$4.94M
10-Q · filed 2026-08-05
$6.80M
derived: sum of 3 quarters · filed 2026-08-05
$7.33M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$3.22M
10-Q · filed 2026-05-07
$5.08M
derived: sum of 2 quarters · filed 2026-05-07
$5.61M
derived: sum of 3 quarters · filed 2026-05-07
$5.56M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$2.39M
derived: sum of 2 quarters · filed 2026-02-26
$2.34M
derived: sum of 3 quarters · filed 2026-08-05
$2.50M
10-K · filed 2026-02-26
2025-09-30$530.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$482.00K
derived: sum of 2 quarters · filed 2026-08-05
$645.00K
10-Q · filed 2025-11-10
$2.45M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$48.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$115.00K
10-Q · filed 2026-08-05
$1.92M
derived: sum of 3 quarters · filed 2026-08-05
$3.26M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$163.00K
10-Q · filed 2026-05-07
$1.97M
derived: sum of 2 quarters · filed 2026-05-07
$3.31M
derived: sum of 3 quarters · filed 2026-05-07
$3.78M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$1.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$3.15M
derived: sum of 2 quarters · filed 2026-02-26
$3.62M
derived: sum of 3 quarters · filed 2026-02-26
$4.21M
10-K · filed 2026-02-26
2024-09-30$1.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$1.81M
derived: sum of 2 quarters · filed 2025-11-10
$2.40M
10-Q · filed 2025-11-10
$2.66M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$471.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$1.06M
10-Q · filed 2025-08-07
$1.31M
derived: sum of 3 quarters · filed 2026-02-26
$2.01M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$590.00K
10-Q · filed 2025-05-08
$843.00K
derived: sum of 2 quarters · filed 2026-02-26
$1.54M
derived: sum of 3 quarters · filed 2026-02-26
$1.84M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$253.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$953.00K
derived: sum of 2 quarters · filed 2026-02-26
$1.25M
derived: sum of 3 quarters · filed 2026-02-26
$1.58M
10-K · filed 2026-02-26
$1.60M
10-K · filed 2024-03-14
2023-09-30$700.00K
10-Q · filed 2023-11-08
$1.00M
derived: sum of 2 quarters · filed 2023-11-08
$1.33M
10-Q · filed 2024-11-07
$21.53M
derived: sum of 4 quarters · filed 2024-05-09
2023-06-30$300.00K
10-Q · filed 2023-08-28
$612.00K
10-Q · filed 2024-08-08
$20.83M
derived: sum of 3 quarters · filed 2024-05-09
$23.43M
derived: sum of 4 quarters · filed 2024-05-09
2023-03-31$335.00K
10-Q · filed 2024-05-09
$20.53M
derived: sum of 2 quarters · filed 2024-05-09
$23.13M
derived: sum of 3 quarters · filed 2024-05-09
$25.23M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$20.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
$22.80M
derived: sum of 2 quarters · filed 2024-03-14
$24.90M
derived: sum of 3 quarters · filed 2024-03-14
$30.20M
10-K · filed 2024-03-14
$30.24M
10-K · filed 2023-03-10
2022-09-30$2.60M
10-Q · filed 2023-11-08
$4.70M
derived: sum of 2 quarters · filed 2023-11-08
$10.00M
10-Q · filed 2023-11-08
$17.97M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$2.10M
10-Q · filed 2023-08-28
$7.43M
10-Q · filed 2023-08-28
$15.37M
derived: sum of 3 quarters · filed 2023-08-28
$17.07M
derived: sum of 4 quarters · filed 2023-08-28
2022-03-31$5.34M
10-Q · filed 2023-05-08
$13.27M
derived: sum of 2 quarters · filed 2023-08-28
$14.97M
derived: sum of 3 quarters · filed 2023-08-28
$15.37M
derived: sum of 4 quarters · filed 2023-08-28
2021-12-31$7.92M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
$9.62M
derived: sum of 2 quarters · filed 2023-08-28
$10.02M
derived: sum of 3 quarters · filed 2023-08-28
$15.05M
10-K/A · filed 2023-08-28
$15.62M
10-K · filed 2022-03-01
2021-09-30$1.70M
10-Q · filed 2022-11-03
$2.10M
derived: sum of 2 quarters · filed 2022-11-03
$7.13M
10-Q · filed 2022-11-03
$9.21M
derived: sum of 4 quarters · filed 2023-08-28
2021-06-30$400.00K
10-Q · filed 2022-08-04
$5.42M
10-Q · filed 2022-08-04
$7.51M
derived: sum of 3 quarters · filed 2023-08-28
$16.01M
derived: sum of 4 quarters · filed 2023-08-28
2021-03-31$5.08M
10-Q · filed 2022-05-09
$7.11M
derived: sum of 2 quarters · filed 2023-08-28
$15.61M
derived: sum of 3 quarters · filed 2023-08-28
$25.51M
derived: sum of 4 quarters · filed 2023-08-28
2020-12-31$2.03M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
$10.53M
derived: sum of 2 quarters · filed 2023-08-28
$20.43M
derived: sum of 3 quarters · filed 2023-08-28
$20.64M
10-K/A · filed 2023-08-28
$20.07M
10-K · filed 2021-02-25
2020-09-30$8.50M
10-Q · filed 2021-11-04
$18.40M
derived: sum of 2 quarters · filed 2021-11-04
$18.61M
10-Q · filed 2021-11-04
$19.68M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$9.90M
10-Q · filed 2021-08-05
$10.09M
10-Q · filed 2021-08-05
$11.18M
derived: sum of 3 quarters · filed 2022-03-01
$14.08M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$139.00K
10-Q · filed 2021-05-10
$1.28M
derived: sum of 2 quarters · filed 2022-03-01
$4.18M
derived: sum of 3 quarters · filed 2022-03-01
$5.48M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$1.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$4.04M
derived: sum of 2 quarters · filed 2022-03-01
$5.34M
derived: sum of 3 quarters · filed 2022-03-01
$7.11M
10-K · filed 2022-03-01
2019-09-30$2.90M
10-Q · filed 2020-11-05
$4.20M
derived: sum of 2 quarters · filed 2020-11-05
$5.97M
10-Q · filed 2020-11-05
$5.86M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$1.30M
10-Q · filed 2020-08-10
$3.02M
10-Q · filed 2020-08-10
$2.96M
derived: sum of 3 quarters · filed 2021-02-25
$2.96M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$1.66M
10-Q · filed 2020-05-05
$1.66M
derived: sum of 2 quarters · filed 2021-02-25
$1.66M
derived: sum of 3 quarters · filed 2021-02-25
$1.66M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$0.00
10-K · filed 2021-02-25
$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$0.00
derived: sum of 2 quarters · filed 2021-02-25
$0.00
derived: sum of 3 quarters · filed 2021-02-25
$0.00
10-K · filed 2021-02-25
2018-09-30$0.00
10-Q · filed 2019-11-12
$0.00
derived: sum of 2 quarters · filed 2019-11-12
$0.00
10-Q · filed 2019-11-12
2018-06-30$0.00
10-Q · filed 2019-08-08
$0.00
10-Q · filed 2019-08-08
2018-03-31$0.00
10-Q · filed 2019-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33